Drug Profile


Alternative Names: CXA-101; CXA-301; FR 264205

Latest Information Update: 15 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Cubist Pharmaceuticals
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Urinary tract infections

Most Recent Events

  • 11 Mar 2013 Ceftolozane licensed to Cubist Pharmaceuticals worldwide
  • 17 Dec 2009 Calixa Therapeutics has been acquired and merged into Cubist Pharmaceuticals
  • 15 Sep 2009 Drug interactions, pharmacokinetics and therapeutic trials data from preclinical trials in Bacterial infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,,,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top